- Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial Bristol-Myers Squibb
- Bristol Myers’ Opdivo stages comeback in bladder cancer, teeing up 2 ‘Merck’ showdowns FiercePharma
- Bristol Myers’ Opdivo extends survival in bladder cancer study Reuters
- First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma OncLive
- Study: Bladder Cancer Drug Extends Survival Newsmax
Tag Archives: Phase
Lilly’s next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz – FierceBiotech
- Lilly’s next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz FierceBiotech
- A new weight-loss drug dubbed the ‘triple G’ could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
- Eli Lilly (LLY) Weight-Loss Shot Gives Company’s Strongest Results in Trial Bloomberg
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM nejm.org
- View Full Coverage on Google News
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA – The Lancet
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet
- American Diabetes Association Highlights Novel Agent Retatrutide which Results in Substantial Weight Reduction in People with Obesity or Type 2 Diabetes During Late Breaking Symposium PR Newswire
- American Diabetes Association Highlights New Developments in Diabetes Technology Pharmacy Times
- American Diabetes Association presentation highlights innovations in technology for diabetic eye condition Ophthalmology Times
- Late Breaking Weight Loss Innovations: New Drug Therapies Shown to Offer Positive Outcomes for Obesity and Type 2 Diabetes Management PR Newswire
- View Full Coverage on Google News
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM – nejm.org
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM nejm.org
- Lilly links oral drug to 15% weight loss, setting bar for Pfizer FierceBiotech
- A new weight-loss drug dubbed the ‘triple G’ could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet
- Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial Medpage Today
- View Full Coverage on Google News
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial – The Lancet
- Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet
- First Vaccine For Chikungunya—An Emerging Mosquito-Borne Threat—Nears After Promising Trial Results Forbes
- Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race BioSpace
- Positive results for potential first chikungunya vaccine – Wed, June 14 2023 The Jakarta Post
- Vaccine Candidate for Chikungunya Virus Safe and Effective Medpage Today
- View Full Coverage on Google News
Vertex-CRISPR drug posts phase 3 wins, secures PDUFA date – FierceBiotech
- Vertex-CRISPR drug posts phase 3 wins, secures PDUFA date FierceBiotech
- CRSP Stock Pops As FDA Sets December Data To Potentially OK Gene-Editing Drug | Investor’s Business Daily Investor’s Business Daily
- FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Yahoo Finance
- Gene Editing Race Between Editas and Vertex, CRISPR Heats Up BioSpace
- Editas posts early sickle cell data as it races to catch Vertex FierceBiotech
- View Full Coverage on Google News
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial – The Lancet
- Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial The Lancet
- Common drug reduces long COVID, University of Minnesota study shows Star Tribune
- New study from UMN researchers says an existing drug is a promising treatment for long COVID MPR News
- Low-Dose Naltrexone Could Treat Long COVID Symptoms Verywell Health
- Study: Using a diabetes medication after testing positive for SARS-CoV-2 reduces risk of developing long COVID by 40% Medical Xpress
- View Full Coverage on Google News
Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer – Neuroscience News
- Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer Neuroscience News
- Study of immunotherapy for brain cancer metastases shows promising results News-Medical.Net
- Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas Science
- New Weapon Against Brain Cancer: Gene Engineered Cell Therapy’s Two-Pronged Assault on Metastatic Melanomas SciTechDaily
- Scientists develop new immuno-therapeutic approach to target brain metastatic melanomas News-Medical.Net
- View Full Coverage on Google News
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca
- Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial AstraZeneca
- AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression Seeking Alpha
- Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
- AstraZeneca’s Tagrisso, chemo combination shows promise in lung cancer trial Reuters
- Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC OncLive
- View Full Coverage on Google News
Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial – The Lancet
- Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial The Lancet
- Innovative therapy brings hope to chronic lower back pain sufferers New Atlas
- Study offers fresh hope for people living with chronic back pain Medical Xpress
- New drug-free treatment offers long-term hope for Australians struggling with back pain | 7NEWS 7NEWS Australia
- Curtin University researchers say back pain treatment trial gives hope to millions ABC News
- View Full Coverage on Google News